Effects of somatostatin on portal vein diameter and biochemical parameters in decompensated liver cirrhosis with upper gastrointestinal bleeding
10.3760/cma.j.issn.1008-6706.2020.12.005
- VernacularTitle:生长抑素对失代偿期肝硬化合并上消化道出血患者门静脉径线及生化指标的影响
- Author:
Zhenhong GUO
1
Author Information
1. 山西省，长治市第二人民医院消化内科 046000
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(12):1427-1430
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of somatostatin on portal vein diameter and biochemical parameters in decompensated cirrhosis with upper gastrointestinal bleeding.Methods:From January 2018 to January 2019, 90 patients with decompensated cirrhosis complicated with upper gastrointestinal bleeding admitted to the gastroenterology department of the Second People's Hospital of Changzhi were selected, and they were divided into two groups according to the random digital table method.The control group(45 cases)was treated with pantoprazole + thrombin, and the observation group(45 cases)was treated with somatostatin on the basis of the control group.The two groups were compared in terms of efficacy, portal vein diameter before and after treatment, biochemical indicators[interleukin-6(IL-6), hypersensitive C-reactive protein(hs-CRP), and procalcitonin(PCT)].Results:The effective rate of the observation group was higher than that of the control group(82.22% vs.62.22%), the difference was statistically significant(χ 2=4.486, P<0.05). After treatment, the anterior and posterior diameter of portal vein in the observation group[(1.12±0.23)cm] was significantly shorter than that in the control group[(1.22±0.22)cm], the difference was statistically significant( t=2.107, P<0.05). The serum levels of IL-6, hs-CRP and PCT were significantly decreased in both two groups after treatment(all P<0.05). The serum levels of IL-6, hs-CRP and PCT in the observation group were(10.32±3.69)ng/L, (13.35±5.46)mg/L, (5.26±1.47)μg/L, which were significantly lower than those in the control group [(15.32±5.69)ng/L, (19.35±7.51)mg/L, (9.45±3.02)μg/L], the differences were statistically significant( t=6.807, 8.433, 10.566, all P<0.05). Conclusion:Somatostatin is effective in the treatment of decompensated cirrhosis with upper gastrointestinal bleeding, which can reduce portal vein dilatation and serum inflammatory factor levels.Somatostatin is effective in the treatment of decompensated cirrhosis with upper gastrointestinal bleeding, which can reduce portal vein dilatation and serum inflammatory factor levels.
